Interstitial Lung Diseases Cohort Study in China

NCT04370158 — Unknown, 3000 participants, China-Japan Friendship Hospital

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT04370158, acronym ILD-China
Status	Unknown
Study type	Observational
Enrollment	3000 (Estimated)
Sponsor	China-Japan Friendship Hospital (Other); collaborators: The First Affiliated Hospital of Guangzhou Medical University, Xiangya Hospital of Central South University, First Hospital of China Medical University, The Fourth Affiliated Hospital of China Medical University, Peking Union Medical College Hospital
Conditions	Interstitial Lung Diseases
Interventions	disease history (Other)
Dates	start 2016-07-01, primary completion 2020-12-31 (estimated), completion 2020-12-31 (estimated), first posted 2020-04-30, last updated 2020-04-30
Locations	1 site in China

-Summary

In this project, the clinical diagnosis of interstitial lung diseases was carried out for the population with suspected interstitial lung diseases selected from the community cohort, and the confirmed patients were included into the existing clinical cohort of interstitial lung diseases, forming an interstitial lung diseases special disease cohort consisting of 3,000 patients and corresponding matched control groups. According to characteristics of interstitial lung disease and the needs of National Key R\&D Program of China, this study will formulate unified clinical follow-up strategy to do long-term standardized clinical follow-up in patients with interstitial lung disease. The detailed information for clinical diagnosis and treatment as well as biological samples were collected to identify disease phenotype and build the database and biological sample library for interstitial lung disease cohort study. This study aims to provide evidence for molecular classification, screening and validation of biomarkers as well as precise diagnosis and prevention in patients with interstitial lung disease.

Expand all sections · Collapse all

+Arms and interventions

disease history (Other): Clinical progression and prognosis of patients with interstitial lung diseases

+Outcome measures

Primary outcomes

Database and biological sample library for Chinese patients with interstitial lung disease [up to 4 years]: Data analyses will be mainly descriptive.

+Eligibility

Sex: All

Inclusion Criteria:

* Physician diagnosed IPF during the last 3 months based upon ATS/ERS/JRS/ALAT guidelines 2011
* Agree to sign the informed consent

Exclusion Criteria:

* Lung transplantation expected within the next 6 months

+Locations (1)

Facility	City	Country	Status
Huaping Dai	Beijing, Beijing Municipality	China	Recruiting

+Publications

Results publication: Meng W, Geng J, Chen X, Dai H. Serum CA125 is independently associated with adverse outcomes in primary Sjogren's syndrome-associated interstitial lung disease: a prospective multicenter cohort study. Respir Res. 2026 Feb 12;27(1):150. doi: 10.1186/s12931-026-03573-x. PMID 41673669
Results publication: Wang H, Liu A, Ni Y, Wang J, Du J, Xi L, Qiang Y, Xie B, Ren Y, Wang S, Geng J, Deng Y, Huang S, Zhang R, Liu M, Dai H; China Interstitial Lung Disease Collaboration Network. Developing and Validation of a Multimodal-Based Machine Learning Model for Diagnosis of Usual Interstitial Pneumonia: A Prospective Multicenter Study. Chest. 2026 Feb;169(2):415-427. doi: 10.1016/j.chest.2025.08.034. Epub 2025 Sep 16. PMID 40967367